These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

125 related items for PubMed ID: 7407769

  • 1. Phase II evaluation of N-(phosphonacetyl-L-aspartic acid (PALA) in patients with advanced colorectal carcinoma.
    Carroll DS, Gralla RJ, Kemeny NE.
    Cancer Treat Rep; 1980; 64(2-3):349-51. PubMed ID: 7407769
    [No Abstract] [Full Text] [Related]

  • 2. Phase II evaluation of N-(phosphonacetyl)-L-aspartic acid (PALA) in metastatic adenocarcinoma of the colon or rectum.
    Van Echo DA, Diggs CH, Scoltock M, Wiernik PH.
    Cancer Treat Rep; 1980; 64(2-3):339-42. PubMed ID: 7407767
    [Abstract] [Full Text] [Related]

  • 3. Phase II study of PALA in advanced large bowel carcinoma.
    Rubin J, Purvis J, Britell JC, Hahn RG, Moertel CG, Schutt AJ.
    Cancer Treat Rep; 1981; 65(3-4):335-6. PubMed ID: 6453645
    [No Abstract] [Full Text] [Related]

  • 4. Phase II evaluation of PALA in patients with metastatic lung cancer.
    Creagan ET, Eagan RT, Fleming TR, Frytak S, Nichols WC, Ingle JN, Kvols LK.
    Cancer Treat Rep; 1981; 65(3-4):356-7. PubMed ID: 7237459
    [No Abstract] [Full Text] [Related]

  • 5. Phase II evaluation of N-(phosphonacetyl)-L-aspartic acid (PALA) in patients with non-small cell carcinoma of the lung.
    Casper ES, Gralla RJ, Kelsen DP, Houghton A, Golbey RB, Young CW.
    Cancer Treat Rep; 1980; 64(4-5):705-7. PubMed ID: 6448688
    [No Abstract] [Full Text] [Related]

  • 6. A randomized phase I and II study of short-term infusion of high-dose fluorouracil with or without N-(phosphonacetyl)-L-aspartic acid in patients with advanced pancreatic and colorectal cancers.
    Ardalan B, Singh G, Silberman H.
    J Clin Oncol; 1988 Jun; 6(6):1053-8. PubMed ID: 3373260
    [Abstract] [Full Text] [Related]

  • 7. A phase II study of PALA (NSC 224131) in patients with advanced ovarian carcinoma. A Gynecologic Oncology Group study.
    Muss HB, Slavik M, Bundy B, Stehman FB, Creasman WT.
    Am J Clin Oncol; 1984 Jun; 7(3):257-60. PubMed ID: 6731346
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Phase I study of N-(phosphonacetyl)-L-aspartic acid (PALA).
    Kovach JS, Schutt AJ, Moertel CG, O'Connell MJ.
    Cancer Treat Rep; 1979 Jun; 63(11-12):1909-12. PubMed ID: 526923
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Continuous five-day infusion of PALA and 5FU: a pilot phase II trial.
    Presant CA, Ardalan B, Multhauf P, Chan C, Staples R, Green L, Browning S, Carr BI, Chang FF, Thayer W.
    Med Pediatr Oncol; 1983 Jun; 11(3):162-3. PubMed ID: 6222250
    [Abstract] [Full Text] [Related]

  • 14. Phase II evaluation of PALA in patients with advanced head and neck cancer.
    Creagan ET, Nichols WC, O'Fallon JR.
    Cancer Treat Rep; 1981 Jun; 65(9-10):827-9. PubMed ID: 7273014
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Chemotherapy for colorectal cancer with a combination of PALA and 5-FU.
    Bedikian AY, Stroehlein JR, Karlin DA, Bennetts RW, Bodey GP, Valdivieso M.
    Cancer Treat Rep; 1981 Jun; 65(9-10):747-53. PubMed ID: 7273010
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Phase II trial of PALA in hypernephroma and urinary bladder cancer.
    Natale RB, Yagoda A, Kelsen DP, Gralla RJ, Watson RC.
    Cancer Treat Rep; 1982 Dec; 66(12):2091-2. PubMed ID: 7139651
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.